Document:

EX-10.2

 Exhibit 10.2 
 Confidential portions of this Exhibit, denoted by bracketed asterisks, have been omitted and filed separately with the Securities and Exchange Commission in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. 
 SECOND AMENDMENT TO AGREEMENT 

THIS SECOND AMENDMENT TO AGREEMENT (this “Second Amendment”) is effective as of April 15, 2013 (the “Second
Amendment Effective Date”), by and between Medisystems Corporation, a Washington corporation (“MDS”) and DaVita Healthcare Partners Inc., a Delaware corporation (“DVA”). The term
“Agreement” as used herein shall mean the Current Agreement (as defined in Recital B) as amended, modified, and supplemented by this Second Amendment and all other capitalized terms used herein but not otherwise defined herein shall
have the meaning ascribed to such terms in the Agreement. NxStage Medical, Inc., a Delaware corporation (“NxStage”), is a party to the Agreement solely for purposes of agreeing to the provisions of Section 11.1 of the Current
Agreement. 
 RECITALS 
 A. MDS and DVA are parties to that certain Agreement, effective as of January 6, 2008 (the “Original Agreement”), whereby MDS agreed to sell the NEEDLE PRODUCTS to DVA through the
MDS CONTRACT DISTRIBUTORS, subject to all of the terms and conditions set forth in the Current Agreement. 
 B. MDS and DVA are
parties to that certain First Amendment to Agreement, effective as of October 16, 2012 (the “First Amendment” and together with the Original Agreement, the “Current Agreement”), whereby MDS and DVA agreed to:
(i) extend the Initial Term from January 5, 2013 to April 15, 2013, (ii) amend and restate in its entirety section 2.3 of the Current Agreement, (iii) amend and restate in its entirety Section 17 of the Current
Agreement, and (iv) [**] for NEEDLE PRODUCTS delivered to DVA on or after January 1, 2013. 
 C. MDS and DVA desire to
enter into this Second Amendment to: (i) extend the Initial Term from April 15, 2013 to December 31, 2013, (ii) provide DVA with the option to either enter into the Two Year Extension or the One Year [**] Period on the terms set
forth in the Agreement, and (iii) amend and restate in its entirety Section 18.5 of the Current Agreement. 
 In
consideration of the foregoing and mutual covenants and agreements contained in this Second Amendment and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be
legally bound, agree as follows: 
 1. Purchase Commitment. Section 1.1 of the Current Agreement is
hereby deleted in its entirety and replaced with the following: 
 “1.1(a) DVA shall [**] during the Initial
Term purchase AVF NEEDLE PRODUCTS (as identified and defined on Schedule A) and BUTTONHOLE NEEDLE PRODUCTS (as identified and defined on Schedule A) (collectively, the “COMMITTED PRODUCTS”) from DVA’s chosen MDS
CONTRACT DISTRIBUTOR sufficient to fulfill at least [**] of DVA’s total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned facilities, including inventory needs, but not including (i) [**] or (ii) [**] unless and
until DVA elects by [**] days written notification to MDS, which notification shall be given by DVA upon the earlier of (X) [**] or (Y) [**] (the “Initial Term Needle Commitment”). 

1.1(b) In the event that DVA enters into the Two Year Extension (as defined in Section 5.1), DVA shall [**] during
the Two Year Extension purchase COMMITTED PRODUCTS from DVA’s chosen MDS CONTRACT DISTRIBUTOR sufficient to fulfill the greater of: (i) [**] of DVA’s total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned
facilities, including inventory needs during each such [**] and (ii) an amount equal to [**] (as defined below) multiplied by [**], but in the cases of each of subparagraphs (i) and (ii) not including (X) [**] or (Y) [**]
unless and until DVA 

 
elects by [**] days written notification to MDS, which notification shall be given by DVA upon the earlier of (I) [**] or (II) [**] (the “Two Year Extension Needle
Commitment”). For purposes of this Agreement, [**]. 
 1.1(c) In the event that DVA enters into the One
Year [**] Period (as defined in Section 5.1) DVA shall: 
  

	 	(i)	during the period of [**] through [**] purchase COMMITTED PRODUCTS from DVA’s chosen MDS CONTRACT DISTRIBUTOR sufficient to fulfill at least [**] of DVA’s
total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned facilities, including inventory needs, but not including (X) [**] or (Y) [**] unless and until DVA elects by [**] days written notification to MDS, which
notification shall be given by DVA upon the earlier of (I) [**] or (II) [**]; 	 

  

	 	(ii)	during the period of [**] through [**] purchase COMMITTED PRODUCTS from DVA’s chosen MDS CONTRACT DISTRIBUTOR sufficient to fulfill at least [**] of DVA’s
total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned facilities, including inventory needs, but not including (X) [**] or (Y) [**] unless and until DVA elects by [**] days written notification to MDS, which
notification shall be given by DVA upon the earlier of (I) [**] or (II) [**]; 	 

  

	 	(iii)	during the period of [**] through [**] purchase COMMITTED PRODUCTS from DVA’s chosen MDS CONTRACT DISTRIBUTOR sufficient to fulfill at least [**] of DVA’s
total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned facilities, including inventory needs, but not including (X) [**] or (Y) [**] unless and until DVA elects by [**] days written notification to MDS, which
notification shall be given by DVA upon the earlier of (I) [**] or (II) [**]; and 	 

  

	 	(iv)	during the period of [**] through [**] purchase COMMITTED PRODUCTS from DVA’s chosen MDS CONTRACT DISTRIBUTOR sufficient to fulfill at least [**] of DVA’s
total requirements (in each equivalents) for COMMITTED PRODUCTS in DVA-owned facilities, including inventory needs, but not including (X) [**] or (Y) [**] unless and until DVA elects by [**] days written notification to MDS, which
notification shall be given by DVA upon the earlier of (I) [**] or (II) [**] (the “One Year [**] Period Needle Commitment” and collectively with the Initial Term Needle Commitment and the Two Year Extension Needle Commitment,
the “NEEDLE COMMITMENT”). 	 

 1.1(d) If during each applicable measurement period during
the Term of this Agreement DVA [**], DVA shall [**] during each such applicable measurement period, and, except for this Section 1.1(d) and the terms of Sections 1.4 and 1.5, MDS shall not be entitled to any other damages or remedy whatsoever.
For purposes of clarity, the parties acknowledge and agree that in the event DVA [**] for any such applicable measurement period. Any [**] pursuant to this Section 1.1(d) shall be made [**] within [**] days of the end of each applicable
measurement period.” 

 2. Taxes. Section 2.3 of the Current Agreement is hereby deleted
in its entirety and replaced with the following: 
 “2.3 MDS covenants and agrees that DVA shall not be
liable for any taxes, including without limitation, any excise, gross receipts, gross earnings, gross value, property, income taxes measured on MDS’ income, or other taxes, other than taxes or charges levied or assessed on or with respect to
the acquisition, possession, or use of the NEEDLE PRODUCTS. MDS covenants and agrees that if at any time during the Term, the [**]. For purposes of this Agreement, the term [**].” 

3. Term. Section 5.1 of the Current Agreement is hereby deleted in its entirety and replaced with the
following: 
 “5.1 Except as otherwise provided herein, unless earlier terminated pursuant to this
Section 5, this Agreement shall be for a term beginning on the Effective Date and ending on December 31, 2013 (the “Initial Term”). On or before October 31, 2013, DVA must notify MDS in writing of its intention to
either (a) extend this Agreement through December 31, 2015 (the “Two Year Extension”) or (b) extend this Agreement through December 31, 2014 (the “One Year [**] Period”). If DVA does not notify
MDS in writing of its intention to either enter into the Two Year Extension or the One Year [**] Period on or before October 31, 2013, then this Agreement shall continue as if DVA had provided written notification to MDS that DVA chose to enter
into the Two Year Extension. In the event that DVA enters into the One Year [**] Period, (i) effective as of January 1, 2014, [**] and (ii) the terms and conditions set forth in Section 2.2 shall no longer be in effect. The
Initial Term together with the Two Year Extension or the One Year [**] Period, as applicable, shall hereinafter collectively be referred to as the “Term”. ” 

4. Notices. Section 18.5 of the Current Agreement is hereby deleted in its entirety and replaced with the
following: 
 “18.5 Any notice required to be given under this Agreement shall be in writing and deemed to
have been given (a) one day following the sending of a facsimile if the sender on the same day sends a confirming copy of such notice by a nationally recognized overnight delivery service (charges prepaid) with instructions for overnight
delivery, (b) five days after the date of mailing if mailed by first class mail, registered or certified mail with return receipt requested (postage prepaid), or (c) one day following traceable delivery to a nationally recognized overnight
delivery service (with charges prepaid) with instructions for overnight delivery, in each case addressed to the appropriate party at the following addresses: 
  

									
		 	(i)	  	MDS:	  		  	Medisystems Corporation
		 		  		  		  	350 Merrimack Street
		 		  		  		  	Lawrence, MA 01843
		 		  		  		  	Attn: President, North America
		 		  		  		  	Phone: (978) 687-4714
		 		  		  		  	Fax: (978) 687-4814
				
		 	With a copy to:	  		  	350 Merrimack Street
		 		  		  		  	Lawrence, MA 01843
		 		  		  		  	Attn: General Counsel
		 		  		  		  	Phone: (978) 687-4725
		 		  		  		  	Fax: (978) 687-4825
					
		 	(ii)	  	NxStage:	  		  	NxStage Medical, Inc.
		 		  		  		  	350 Merrimack Street
		 		  		  		  	Lawrence, MA 01843
		 		  		  		  	Attn: President, North America
		 		  		  		  	Phone: (978) 687-4714
		 		  		  		  	Fax: (978) 687-4814

									
		 		 	 With a copy to:
	  	350 Merrimack Street
		 		 		  		  	Lawrence, MA 01843
		 		 		  		  	Attn: General Counsel
		 		 		  		  	Phone: (978) 687-4725
		 		 		  		  	Fax: (978) 687-4825
					
		 		 	(iii)	  	DVA	  	DaVita Healthcare Partners Inc.
		 		 		  		  	900 7th Street, NW Suite 680
		 		 		  		  	Washington, DC 20001
		 		 		  		  	Attn: Group Vice President
		 		 		  		  	Phone: (202) 789-6910
		 		 		  		  	Fax: (866) 445-0435
				
		 		 	With a copy to:	  	DaVita Healthcare Partners Inc.
		 		 		  		  	2000 16th St.
		 		 		  		  	Denver, CO 80202
		 		 		  		  	Attn: Chief Legal Officer
		 		 		  		  	Phone: (303) 405-2000
		 		 		  		  	Fax: (303) 876-0963

 The above addresses and facsimile numbers may be changed by written notice to the other party, provided
that no notice of a change of address or facsimile number will be effective until actual receipt of such notice.” 
 5. Governing Law. All issues and questions concerning the construction, validity, enforcement, and interpretation of this Second Amendment shall be governed by and construed in accordance with the
laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions. 
 6. No Other Changes. Except as expressly modified in this Second Amendment, all other terms and conditions of the Current Agreement remain unchanged and in full force and effect and shall govern
and apply to all matters contemplated by this Second Amendment. 
 7. Counterparts and
Facsimile/PDF Signatures. This Second Amendment may be executed in any number of counterparts, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and
the same instrument. The parties hereto agree that facsimile transmission or PDF of original signatures shall constitute and be accepted as original signatures. 

8. Severability. In the event that any provision of this Second Amendment shall be held to be
invalid or unenforceable in any respect, such provision shall be enforced to the fullest extent permitted by law and the remaining provisions of this Second Amendment shall remain in full force and effect. If any such invalid portion constitutes a
material term of this Second Amendment, the parties hereto shall meet and in good faith seek to mutually agree to modify this Second Amendment so as to retain, if possible, the overall essential terms of this Second Amendment. 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be executed by
their duly authorized representatives and effective as of the Second Amendment Effective Date. 
  

					
	MDS:	 		 	DVA:
	MEDISYSTEMS CORPORATION	 		 	DAVITA HEALTHCARE PARTNERS INC.
			
	 By: /s/ Jeffrey H. Burbank
	 		 	 By: /s/ Leanne Zumwalt

	Print Name: Jeffrey H. Burbank	 		 	Print Name: Leanne Zumwalt
	Title: President	 		 	Title: GVP

  

					
		 	 NXSTAGE: (Solely for purposes of agreeing to be

bound by Section 11.1 of the Current Agreement)

		 	NXSTAGE MEDICAL, INC.	 	
			
		 	 By: /s/ Jeffrey H. Burbank
	 	
		 	Print Name: Jeffrey H. Burbank	 	
		 	Title: CEOExhibit 10.2

 EXHIBIT 10.2 
 Offer of Appointment 
 May 24th 2013 
 Mr. Gerhard Watzinger 
 2821 Tar Flower Way, 

Naples, FL 34105 
 Dear Gerhard, 

We are pleased to confirm our Offer of Appointment (“Agreement”) for the position of Chief Executive Officer &
President, on interim basis with iGATE Corporation (“hereafter referred to as “iGATE” or “Company”) on the following terms and conditions. Your employment will be effective from 20th May 2013 (“Effective Date”) at iGATE. 

 

	1.	Compensation: You shall be compensated per details in Annexure A. Compensation, subject to all applicable taxes and withholdings, will be paid on a bi-monthly
basis for your services. 

  

	2.	Term: The term of this Agreement (Term) will commence as of the Effective Date and will continue until the earlier of the date a permanent Chief Executive
Officer & President is appointed by the Board of Directors of the Company and commences to serve or the date this Agreement is terminated pursuant to the terms of this Agreement. 

 

	3.	Termination: You agree to provide the Company with thirty (30) days advance notice of your termination of this Agreement and the Company agrees to provide
you with thirty (30) days advance notice of its termination of your employment, except in cases of termination by the Company due to the appoint of a successor Chief Executive Office & President or termination due to your willful
misconduct or non-performance, in which case the termination would be effective immediately. 

  

	4.	Confidentiality: As a part of your employment, you will acquire or develop confidential and proprietary information concerning the Company and its
dealings/method of dealings and you also will develop relationships of special trust and confidence with the Company’s customers (and their end-users) and Employees (collectively, referred to as “Confidential Matter”). You agree that
such Confidential Matter is for the Company’s exclusive benefit and that, both during your employment and at all times thereafter, you will not directly or indirectly use or disclose any Confidential Matter except for the sole benefit and with
the consent of the Company. Upon the conclusion of your employment, you will promptly return all documents and information (including computer generated or stored matters) concerning the Company or its customers (and their end-users) or Employees
and also all personal property of the Company provided by the Company for your use (i.e., items such as laptop computer, cell phone and, data card). 

  

	5.	Non-Solicitation: 

 During
the six (6) month period following the termination of your employment for whatever reason, you shall not directly or indirectly solicit or retain or hire the services of (or otherwise deal in a manner adverse to the Company with) any Employee
of the Company or induce such Employee to terminate his or her employment. 
 This Agreement along with sets forth the full and complete
understanding and agreement of the parties with respect to its subject matter and supersedes all prior discussions, negotiations and agreements. This Agreement may be modified only by means of a writing signed by both parties. Each of the parties
has executed this Agreement as provided below with the express intent to be legally bound. This Agreement shall come into effect on the Effective Date at iGATE. 

  
 1 of 3

 We look forward to your association with iGATE over the long term and nurturing a mutually beneficial
relationship. 
  
  

					
	Sincerely	 		 	 Agreed to and Accepted with the

Intent to be Legally Bound

			
	  	 		 	  
	Sunil Wadhwani	 		 	Gerhard Watzinger
	 Co-Chairman
 iGATE
Corporation
	 		 	  
		 		 	(Date)
			
	 	 		 	  
		 		 	(SSN: ###-##-####)

  
 2 of 3

 ANNEXURE A 

This Annexure is issued pursuant to Offer of Appointment dated May 20th 2013 (“Agreement”), between iGATE Corporation
(“iGATE” or “Company”) and Gerhard Watzinger, whereby iGATE agrees to pay as per details given below. 
  

									
	Effective Date:	 	May 20th 2013	  	
	Compensation:	 	$100,000.00 USD per month (pro-rated for period less than a month)

 Both parties have executed this Annexure with the express intent to be legally bound hereby. Any changes to the above
must be set forth in a written document signed by both parties, and any oral modifications shall be deemed void and shall have no effect. 
  

							
	 Agreed to:
  
 iGATE Corporation
	 		 	 Agreed to:
  

Gerhard Watzinger

			
	  	 		 	  
	Sunil Wadhwani	 		 	Signature
	 Co-Chairman
 iGATE
Corporation
	 		 	 	 	 
				
	May 24th 2013	 		 	Date	 	  

  
 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]